Subsequent molecular biology experiments demonstrated that brusatol ameliorates psoriasis-associated dyslipidemia by modulating the AMPK-mediated SREBP-1c/FASN and PPARα/CPT1A signaling pathways. Here, PPARA is linked to psoriasis.